The work, summarized in a Research Briefing by Nature Biotechnology, combines two ingredients that have rarely been brought together so systematically: high-throughput experimentation and Bayesian optimization. Bayesian optimization is a machine learning strategy designed for exactly the kind of problem the vaccine engineers faced, in which each experiment is costly, the search space of possible formulations is vast, and the relationship between the ingredients and the outcome is complex and poorly understood. Rather than testing every conceivable combination of stabilizing sugars, buffering agents, drying protocols and nanoparticle compositions, the algorithm builds a probabilistic model of the formulation landscape from the data gathered so far, then selects the next experiment where the expected gain in information or performance is highest.

This data-efficient approach matters because traditional formulation development is notoriously slow. A medicinal chemist or vaccine formulator might adjust one variable at a time, run stability assays that take days or weeks to complete, and iterate over months or years. By contrast, AGENT closes the loop: robotic high-throughput platforms prepare large batches of candidate formulations, automated assays measure their stability and bioactivity, and the Bayesian optimizer digests each round of results to propose an improved set of conditions for the next. The framework effectively takes the human out of the loop for the routine decision-making, reserving human judgment for defining the objectives and validating the final candidates.

The target of the optimization was a solid-state mRNA vaccine, meaning that the mRNA-lipid nanoparticles are dried into a stable matrix rather than suspended in liquid. Drying is a well-known route to thermal stability for biological drugs, as the absence of water dramatically slows the hydrolysis and other degradation reactions that destroy RNA. But the drying process itself is stressful: ice crystals, osmotic shocks and the removal of the hydration shell can shear nanoparticles, aggregate them, or otherwise wreck the delicate structure that allows them to fuse with cell membranes and release their payload. The art lies in choosing protective excipients, often sugars such as trehalose or sucrose, and processing conditions that let the nanoparticles pass through drying and reconstitution unscathed.

The results reported by Tian and colleagues are striking on several fronts. The optimized solid-state formulations retained full bioactivity after two months of storage at 37 degrees Celsius, a condition far beyond anything current liquid mRNA vaccines can tolerate. In immunization studies, these stored vaccines elicited immune responses that were non-inferior to those generated by fresh, never-stressed formulations, which is the critical regulatory benchmark: a thermostable vaccine is only useful if it works as well as the product it replaces. Stability at room temperature and above would allow vaccines to be shipped and stored without the elaborate cold chain of ultra-low-temperature freezers, dry ice and temperature loggers that dominates current distribution.

The team went beyond vials and syringes. The thermostable mRNA formulations were incorporated into microneedle patches, small arrays of dissolving needles that painlessly deliver vaccine into the skin. Microneedle delivery has been pursued for years as a needle-free, potentially self-administered vaccination platform, and earlier work from some of the same community demonstrated a microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. The new study extends that vision by showing that the AI-optimized, cold-chain-free formulations could be delivered via microneedle patches in rodents and nonhuman primates, providing proof of concept in animals that are far closer to humans than cell cultures or mice alone.

The combination of thermostability and patch delivery points toward a fundamentally different model of vaccine distribution. A vaccine that survives months at 37 degrees Celsius and can be applied as a patch requires no freezer, no trained phlebotomist, no reconstitution step and minimal medical waste. In resource-constrained settings, where the cited literature on vaccine accessibility emphasizes that storage and distribution bottlenecks cost lives, such a product could reach communities that conventional campaigns struggle to serve. It would also simplify pandemic preparedness, since stockpiles would not depend on a continuous chain of refrigeration stretching from factory to clinic.

From a technical standpoint, the study is a showcase of how modern machine learning changes the economics of formulation science. Bayesian optimization is particularly suited to problems with expensive evaluations because it balances exploration and exploitation: it probes regions of the design space where the model is uncertain, while also refining candidates that already look promising. The framework’s data efficiency means that the number of physical experiments needed to reach an optimized formulation can be a fraction of what a grid search or one-variable-at-a-time approach would demand. Each experiment feeds back into a surrogate model, typically a Gaussian process or similar probabilistic regressor, which quantifies not just the predicted performance of untested formulations but the confidence in those predictions.

The subjects attached to the paper, spanning biomaterials for vaccines, biomedical engineering, DNA and RNA science, and nanoparticles, reflect the interdisciplinary nature of the achievement. The mRNA-lipid nanoparticle platform sits at the intersection of nucleic acid chemistry, colloid science, polymer physics and immunology, and no single discipline could have solved the stability problem alone. What AGENT contributes is a unifying optimization layer that treats the entire formulation-and-processing pipeline as a single search problem, allowing trade-offs to be navigated automatically. A choice of excipient that improves drying stability but slows release, for example, can be weighed against alternatives in a principled way rather than by intuition.

Caveats remain, as they always do at this stage of translation. The immunogenicity data are from rodents and nonhuman primates, and human clinical trials will be needed to confirm that the optimized solid-state vaccines match the performance of approved liquid products in people. Two months of stability at 37 degrees Celsius is a dramatic improvement, but regulators will want to see longer-term data across a range of temperatures and humidities, along with manufacturing scale-up studies. Nonetheless, the demonstration that an AI-driven, data-efficient framework can compress years of formulation development into a rapid, systematic campaign is itself a significant result. If the approach generalizes to other mRNA drugs and vaccine targets, the cold chain that has long constrained global health delivery may finally begin to loosen.

Subject of Research: AI-guided Bayesian optimization for the development of thermostable, solid-state mRNA-lipid nanoparticle vaccines

Article Title: AI-guided optimization for thermostable mRNA vaccines

Article References: AI-guided optimization for thermostable mRNA vaccines. (2026). Nature Biotechnology. https://doi.org/10.1038/s41587-026-03330-x

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03330-x

Keywords: mRNA vaccines, artificial intelligence, Bayesian optimization, lipid nanoparticles, thermostability, cold chain, microneedle patches, high-throughput experimentation, vaccine formulation, global health, biotechnology, immunization

Oak Brook, IL – Volume 36 of SLAS Technology includes two editorials, one literature highlight, two original research articles, two reviews and two Special Issue (SI) features.

Editorials

• Mass Spectrometry Applications for High-Throughput Experimentation in Supporting Drug Discovery
  High-throughput experimentation paired with mass spectrometry (MS) is accelerating drug discovery by enabling rapid, parallel analysis of thousands of chemical reactions and biological assays. While challenges such as data management and matrix effects remain, advances in MS technology, direct-to-biology workflows and AI integration are driving end-to-end optimization of the drug discovery process.
• 2^nd EUOS/SLAS Joint Challenge: Prediction of Spectral Properties of Compounds
  The Second Joint Machine Learning Challenge, built on the success of the first EU-OPENSCREEN/SLAS challenge, demonstrates how open, well-curated experimental datasets can accelerate the development of advanced machine learning methods for drug discovery. The editorial outlines the challenge–the full technical descriptions of the winning solutions will be published in SLAS Technology later this year.

Reviews

• Guide to Liquid Volume Measurements: A Review of Methods and Technologies
  This review surveys liquid volume measurement methods and technologies for life science laboratories, covering volumes from picoliters to milliliters across applications in biopharmaceutical and clinical settings. Key attributes evaluated include volume range, precision, accuracy, workflow integration and regulatory compliance.
• Toward Full Automation in Synthetic Biology: A Progressive Conceptual Framework Integrating Robotics and Intelligent Agents
  This article examines the role of robotics and AI in automating synthetic biology workflows, covering progress of physical and cognitive automation in synthetic biology. The authors propose a dual framework for both total automation of the full Design-Build-Test-Learn cycle and progressive automation that can be adapted to diverse laboratory contexts, while addressing the ethical considerations of increasingly autonomous biological research.

Original Research

• Implementation of a Modular Digital Laboratory Infrastructure for SiLA₂ Based Devices
  This article presents a laboratory digitalization framework using open-source software and hardware, demonstrated through a SiLA-based continuous chromatography system for Green Fluorescent Protein (GFP) purification. The framework includes device control, data management, evaluation, and maintenance strategies for software and hardware.
• Low-Cost CNC-Based Media Dispensing System for Biotechnology Laboratories
  A custom Computer Numerical Control-based Automated Media Dispensing System was developed and validated over two years for a plant biotechnology lab, outperforming manual dispensing while maintaining efficiency At approximately one-fiftieth the cost of comparable commercial systems, the modular design offers an accessible and ergonomic automation solution for research laboratories.

Literature Highlight

• Life Sciences and Aging
  This entry in the Life Sciences and Society series by SLAS Technology Associate Editor Kerstin Thurow, PhD, centers on advances in genomics, AI, and senolytic therapies that are giving life sciences increased power to intervene in the aging process, shifting the focus toward extending healthy lifespan rather than longevity alone.

Special Issues

• Robotics in Laboratory Automation
  This editorial introduces the Special Issue (SI) Robotics in Laboratory Automation, which highlights advances in robotic systems that improve experimental precision, reproducibility and throughput. The SI addresses key developments in standardization and intelligent automation while acknowledging current limitations and emerging trends shaping the field.
• Revolutionizing Transcriptomics from Single-Cell Insights to RNA-Based Interventions
  This SI on systems genetics examines gene and molecular interaction networks, utilizing high-throughput sequencing and multi-omics technologies to understand how genetic networks influence phenotypes. It emphasizes the significance of personalized medicine, therapeutic target discovery and biomarker identification through integrated genomic and epigenomic approaches.

All active SLAS Discovery and SLAS Technology call for papers are available at:

This volume of SLAS Technology is available at

*****

SLAS Technology reveals how scientists adapt technological advancements for life sciences exploration and experimentation in biomedical research and development. The journal emphasizes scientific and technical advances that enable and improve:

• Life sciences research and development
• Drug delivery
• Diagnostics
• Biomedical and molecular imaging
• Personalized and precision medicine

SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Technology: Translating Life Sciences Innovation, 2024 Impact Factor 3.7. Editor-in-Chief Edward Kai-Hua Chow, PhD, KYAN Technologies, Los Angeles, CA (USA).

###

Journal

SLAS TECHNOLOGY